ZYMEDI
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases.
ZYMEDI
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2019-12-01
Address:
Ansan, Inch'on-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.zymedi.com
Total Employee:
11+
Status:
Active
Contact:
+82 32 822 8376
Email Addresses:
[email protected]
Technology used in webpage:
Euro South Korean Server Location
Similar Organizations
ARTham Therapeutics
ARTham Therapeutics is a biopharmaceutical company that delivers drugs to help patients.
Iol Chemicals & Pharmaceutical
Iol Chemicals & Pharmaceutical is a generic pharmaceutical company specializing in various therapeutic categories.
PRD Therapeutics
PRD Therapeutics is a pharmaceutical company that develops medicines for different metabolic diseases.
Surface Ophthalmics
Surface Ophthalmics is a pharmaceutical company that develops therapeutics for the treatment of ocular diseases.
Investors List
Company K Partners
Company K Partners investment in Venture Round - Zymedi
IMM Investment
IMM Investment investment in Venture Round - Zymedi
Official Site Inspections
http://www.zymedi.com Semrush global rank: 10.87 M Semrush visits lastest month: 198
- Host name: 211.115.73.20
- IP address: 211.115.73.20
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Zymedi"
Zymedi - Home - Zymedi
Our mission is to identify novel therapeutics for life-threatening diseases that have no standard of care or lack effective therapy. We are dedicated to treating diseases with significant unmet needs by expanding the promise of precision …See details»
Zymedi - Crunchbase Company Profile & Funding
Zymedi has 2 investors including Company K Partners and IMM Investment. When was the last funding round for Zymedi? Zymedi closed its last funding …See details»
About Us - Zymedi
About Us Zymedi 2024-08-21T05:28:02+00:00 Inspired by our vision of a disease-free world ZYMEDI is inspired by a long-term vision to create a disease- free world with therapies for even the most challenging diseases.See details»
Zymedi Company Profile 2024: Valuation, Funding & Investors
Zymedi General Information Description. Developer of novel therapeutics platform intended to improve the quality of life of people suffering from diseases. The company's platform focuses …See details»
Our Leadership - Zymedi
With extensive expertise in ARS-based early drug discovery, Nam Hoon Kwon brings a wealth of knowledge and experience to ZYMEDI. With a PhD from Seoul University and a DVM in …See details»
Zymedi - LinkedIn
Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for …See details»
Zymedi | VentureRadar
At ZYMEDI we are putting our extensive knowledge of aminoacyl-tRNA synthetase (ARS) science to work to transform the next generation of drug discovery. Focused on the most challenging …See details»
Zymedi - Funding, Financials, Valuation & Investors - Crunchbase
Jan 1, 2021 Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. …See details»
Zymedi - Products, Competitors, Financials, Employees, …
Zymedi. Frequently Asked Questions (FAQ) When was Zymedi founded? Zymedi was founded in 2019. Where is Zymedi's headquarters? Zymedi's headquarters is located at 85 …See details»
Zymedi - Company Profile - Tracxn
Dec 7, 2024 Zymedi. has raised a total funding of $29.5M over 2 rounds. Its first funding round was on 2021. What are the most recent funding rounds of Zymedi? Its latest funding round …See details»
Zymedi Co. Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Zymedi will work with clinical investigators and researchers of the Intramural NIH PAH Translational Research Team to conduct a Phase 1, First-in-Human Clinical Trial in …See details»
About Us - Zymedi
About Us Zymedi 2022-12-16T21:34:04+00:00. Page load link. Go to Top. Notifications ...See details»
Zymedi Co. Ltd. (Zymedi Co. Ltd.) - 药物管线_专利_临床试验_投融 …
SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development …See details»
ZYMEDI - BIO CEO & Investor Conference | BIO
Feb 7, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... ZYMEDI is …See details»
Zymedi - BIO International Convention 2024
Jun 5, 2024 Zymedi Add to Calendar. Wednesday, June 05, 2024 4:45 PM - 5:00 PM Company Presentation. Inflammation Company Presentation Theater 1 Zymedi is a clinical stage new …See details»
Our Investors - Zymedi
As a company, ZYMEDI has the ability and flexibility to partner on a variety of different levels, including R&D joint ventures, strategic investments, and in-licensing. Our purpose to transform …See details»
Zymedi-动脉网 - vbdata.cn
生物制药公司Zymedi肺动脉高压治疗药物ZMA001获FDA孤儿药资格认定 2024-07-31 风险投资公司Zymedi宣布与美国心肺与血液研究所就候选药物ZMA001签署一项临床合作研究与开发协议 …See details»
Our Platform - Zymedi
Our in-house drug discovery platform is named HOMEOS, after ARSs’ capability of maintaining homeostasis. Also known as AIDD (aminoacyl-tRNA synthetase [ARS]-focused integrated …See details»
Our Pipeline - Zymedi
At ZYMEDI we are putting our extensive knowledge of aminoacyl-tRNA synthetase (ARS) science to work to transform the next generation of drug discovery.Focused on the most challenging …See details»